|
Viragen to Present at New York Biotech Forum PLANTATION, Fla., June 2 /PRNewswire-FirstCall/ -- Viragen, Inc. (Amex: VRA) today announced that the Company is scheduled to present at the Informed Investors Biotechnology and Pharmaceutical Stocks Forum at the Princeton Club in New York City on June 23. The analyst-style forum, which is to include a presentation from Viragen`s President and CEO, Charles A. Rice, will be webcast following the close of the live event. "I am looking forward to presenting Viragen`s strategy to institutional investors, not only at this conference, but also in individual meetings which have been arranged in New York and London this month," stated Mr. Rice. "With a new financing and recapitalization strategy hopefully completed by mid-June, these meetings will be important steps for communicating the investment and growth opportunities that I believe Viragen represents." Event: Informed Investors Biotechnology and Pharmaceutical Stocks Forum When: 8:30 a.m. (EDT) Where: The Princeton Club, 15 West 43rd St. (Between 5th and 6th Avenues) Fee to attend: $30 (There is no charge for webcast replay) Keynote Speakers: Lynn Sutherland, President of Sutherland Consulting & Bill Alpert, Senior Editor and Biotechnology Writer for Barron`s To register, please visit: http://www.informedinvestors.com/CustomEvent/85117/index.asp… About Viragen, Inc.: Viragen is a biotechnology company specializing in the research, development and commercialization of natural and recombinant protein-based drugs designed to treat a broad range of viral and malignant diseases. These protein-based drugs include natural human alpha interferon, monoclonal antibodies and a peptide drug. Viragen`s strategy also includes the development of Avian Transgenic Technology as a biomanufacturing platform for the large-scale, cost-effective production of therapeutic proteins. Fraktal |
|
| aus der Diskussion: | Viragen - aktueller Artikel im Science Magazin |
| Autor (Datum des Eintrages): | Frakt@l (02.06.04 19:27:49) |
| Beitrag: | 121 von 128 (ID:13286321) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |